Open AccessAssessment on anti-SARS-CoV-2 receptor-binding domain antibodies among CoronaVac-vaccinated Indonesian adults
Author(s) -
Juandy Jo,
Astia Sanjaya,
Reinhard Pitoan,
Maroloan Aruan,
Rury Mega Wahyuni,
Venansi Viktaria
Publication year - 2022
Publication title -
clinical and experimental vaccine research
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 0.958
H-Index - 11
eISSN - 2287-366X
pISSN - 2287-3651
DOI - 10.7774/cevr.2022.11.1.116
Subject(s) - medicine , seroconversion , immunogenicity , antibody , titer , covid-19 , coronavirus , virology , indonesian , serology , immunology , disease , infectious disease (medical specialty) , linguistics , philosophy
The immunogenicity of CoronaVac among Indonesian adults at the academic premises was investigated. Two doses of CoronaVac vaccine induced a complete seroconversion on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) naïve adults with titers of anti-SARS-CoV-2 receptor-binding domain (RBD) antibodies ranging from 9.1 to 151.9 U/mL. The median value was lower than the one observed in recovered adults with mild coronavirus disease 2019 (38.7 vs. 114.5 U/mL). Nonetheless, 93.6% of the vaccinated adults, in contrast to 76.5% of the recovered adults, displayed inhibition rates above the cut-off to block RBD-angiotensin-converting enzyme 2 binding. This suggests that two doses of CoronaVac were immunogenic and likely to be protective among Indonesian adults.